NO309095B1 - AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt fibronektinbindende peptid - Google Patents

AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt fibronektinbindende peptid Download PDF

Info

Publication number: NO309095B1
Authority: NO; Norway
Prior art keywords: peptide; fibronectin; binding; activity; produced
Prior art date: 1990-08-10

Application number

NO921407A

Other languages

English (en)

Norwegian (no)

Other versions

NO921407L (no

NO921407D0 (no

Inventor

Magnus Hoeoek

Martin Mcgavin

Guiseppe Raucci

Original Assignee

Alfa Laval Agri Internat Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-10

Filing date

1992-04-09

Publication date

2000-12-11

1992-04-09 Application filed by Alfa Laval Agri Internat Ab filed Critical Alfa Laval Agri Internat Ab

1992-04-09 Publication of NO921407D0 publication Critical patent/NO921407D0/no

1992-06-05 Publication of NO921407L publication Critical patent/NO921407L/no

2000-12-11 Publication of NO309095B1 publication Critical patent/NO309095B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 95
230000027455 binding Effects 0.000 title claims abstract description 52
108010067306 Fibronectins Proteins 0.000 title claims description 61
102000016359 Fibronectins Human genes 0.000 title claims description 61
238000004519 manufacturing process Methods 0.000 title claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
239000001257 hydrogen Substances 0.000 claims abstract description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
150000001413 amino acids Chemical class 0.000 claims description 17
238000000034 method Methods 0.000 claims description 13
238000003776 cleavage reaction Methods 0.000 claims description 11
230000007017 scission Effects 0.000 claims description 11
238000007385 chemical modification Methods 0.000 claims description 9
238000003786 synthesis reaction Methods 0.000 claims description 7
239000012634 fragment Substances 0.000 claims description 6
238000000746 purification Methods 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 4
239000007791 liquid phase Substances 0.000 claims 3
238000010532 solid phase synthesis reaction Methods 0.000 claims 3
125000003275 alpha amino acid group Chemical group 0.000 claims 2
238000002955 isolation Methods 0.000 claims 1
230000000694 effects Effects 0.000 description 20
102000004196 processed proteins & peptides Human genes 0.000 description 20
230000029087 digestion Effects 0.000 description 17
210000004027 cell Anatomy 0.000 description 14
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
206010052428 Wound Diseases 0.000 description 12
208000027418 Wounds and injury Diseases 0.000 description 12
239000000047 product Substances 0.000 description 12
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
239000004472 Lysine Substances 0.000 description 11
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
239000002953 phosphate buffered saline Substances 0.000 description 11
108010040923 D3 peptide Proteins 0.000 description 10
108090000631 Trypsin Proteins 0.000 description 10
102000004142 Trypsin Human genes 0.000 description 10
230000004071 biological effect Effects 0.000 description 10
239000012588 trypsin Substances 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 9
238000003556 assay Methods 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
108090000317 Chymotrypsin Proteins 0.000 description 8
101710118538 Protease Proteins 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
229960002376 chymotrypsin Drugs 0.000 description 8
230000009467 reduction Effects 0.000 description 8
238000006722 reduction reaction Methods 0.000 description 8
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
239000000758 substrate Substances 0.000 description 7
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 5
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
238000001212 derivatisation Methods 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical class COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
238000004007 reversed phase HPLC Methods 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
102000035195 Peptidases Human genes 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
239000004365 Protease Substances 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
102000036072 fibronectin binding proteins Human genes 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000008520 organization Effects 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
238000002255 vaccination Methods 0.000 description 4
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
108010051815 Glutamyl endopeptidase Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
241000589886 Treponema Species 0.000 description 3
241000223109 Trypanosoma cruzi Species 0.000 description 3
235000012538 ammonium bicarbonate Nutrition 0.000 description 3
239000001099 ammonium carbonate Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
210000002808 connective tissue Anatomy 0.000 description 3
UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
108091010988 fibronectin binding proteins Proteins 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000003446 ligand Substances 0.000 description 3
208000004396 mastitis Diseases 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000006337 proteolytic cleavage Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
108010017707 Fibronectin Receptors Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
206010041925 Staphylococcal infections Diseases 0.000 description 2
229940122618 Trypsin inhibitor Drugs 0.000 description 2
101710162629 Trypsin inhibitor Proteins 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000026045 iodination Effects 0.000 description 2
238000006192 iodination reaction Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
230000007923 virulence factor Effects 0.000 description 2
239000000304 virulence factor Substances 0.000 description 2
229920001817 Agar Polymers 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
238000006214 Clemmensen reduction reaction Methods 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241001622557 Hesperia Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 1
241000282849 Ruminantia Species 0.000 description 1
241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 1
241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
206010072170 Skin wound Diseases 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
108010088160 Staphylococcal Protein A Proteins 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 1
NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
108090001109 Thermolysin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010048038 Wound infection Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000011324 bead Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
238000011540 hip replacement Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000003685 thermal hair damage Effects 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000009736 wetting Methods 0.000 description 1
230000037314 wound repair Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Dermatology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Immunology (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO921407A 1990-08-10 1992-04-09 AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt fibronektinbindende peptid NO309095B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9002617A SE9002617D0 (sv)	1990-08-10	1990-08-10	A fibronectin binding peptide
PCT/SE1991/000534 WO1992002555A1 (fr)	1990-08-10	1991-08-09	Peptide liant de la fibronectine

Publications (3)

Publication Number	Publication Date
NO921407D0 NO921407D0 (no)	1992-04-09
NO921407L NO921407L (no)	1992-06-05
NO309095B1 true NO309095B1 (no)	2000-12-11

Family

ID=20380128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO921407A NO309095B1 (no)	1990-08-10	1992-04-09	AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt fibronektinbindende peptid

Country Status (15)

Country	Link
EP (1)	EP0504335B1 (fr)
JP (1)	JPH05502046A (fr)
AT (1)	ATE161018T1 (fr)
AU (1)	AU632001B2 (fr)
CA (1)	CA2067233C (fr)
DE (1)	DE69128416T2 (fr)
DK (1)	DK0504335T3 (fr)
ES (1)	ES2112862T3 (fr)
FI (1)	FI106264B (fr)
GR (1)	GR3026307T3 (fr)
HU (1)	HU219261B (fr)
IE (1)	IE912836A1 (fr)
NO (1)	NO309095B1 (fr)
SE (1)	SE9002617D0 (fr)
WO (1)	WO1992002555A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8801894D0 (sv) *	1988-05-20	1988-05-20	Alfa Laval Agri Int	Fibronektinbindande protein
SE8901687D0 (sv) *	1989-05-11	1989-05-11	Alfa Laval Agri Int	Fibronectin binding protein as well as its preparation
US5440014A (en) *	1990-08-10	1995-08-08	H+E,Uml/Oo/ K; Magnus	Fibronectin binding peptide
US5980908A (en) *	1991-12-05	1999-11-09	Alfa Laval Ab	Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
ES2243926T3 (es) *	1993-02-05	2005-12-01	Smithkline Beecham Plc	Proteina de union de fibronectina; anticuerpo monoclonal y su uso para prevenir la adhesion bacteriana.
US5955078A (en) *	1993-02-05	1999-09-21	Smithkline Beecham P.L.C.	Fibronectin binding protein polypeptides
US5648240A (en) *	1994-05-24	1997-07-15	Texas A&M University	MHC II analog from Staphylococcus aureus
GB9415901D0 (en) *	1994-08-05	1994-09-28	Smithkline Beecham Plc	Novel compounds and treatment
CA2277793A1 (fr) *	1997-01-21	1998-07-23	The Texas A & M University System	Compositions de proteines se liant a la fibronectine et leurs procedes d'utilisation
US6685943B1 (en)	1997-01-21	2004-02-03	The Texas A&M University System	Fibronectin binding protein compositions and methods of use
US7115264B2 (en)	2001-11-05	2006-10-03	Inhibitex	Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8702272L (sv) *	1987-06-01	1988-12-02	Alfa Laval Agri Int	Fibronektinbindande protein samt dess framstaellning

1990
- 1990-08-10 SE SE9002617A patent/SE9002617D0/xx unknown
1991
- 1991-08-09 DE DE69128416T patent/DE69128416T2/de not_active Expired - Lifetime
- 1991-08-09 WO PCT/SE1991/000534 patent/WO1992002555A1/fr not_active Ceased
- 1991-08-09 DK DK91914903T patent/DK0504335T3/da active
- 1991-08-09 AU AU84118/91A patent/AU632001B2/en not_active Expired
- 1991-08-09 HU HU9201211A patent/HU219261B/hu unknown
- 1991-08-09 AT AT91914903T patent/ATE161018T1/de not_active IP Right Cessation
- 1991-08-09 EP EP91914903A patent/EP0504335B1/fr not_active Expired - Lifetime
- 1991-08-09 ES ES91914903T patent/ES2112862T3/es not_active Expired - Lifetime
- 1991-08-09 CA CA002067233A patent/CA2067233C/fr not_active Expired - Lifetime
- 1991-08-09 JP JP3514015A patent/JPH05502046A/ja active Pending
- 1991-08-12 IE IE283691A patent/IE912836A1/en not_active IP Right Cessation
1992
- 1992-04-09 NO NO921407A patent/NO309095B1/no not_active IP Right Cessation
- 1992-04-09 FI FI921582A patent/FI106264B/fi not_active IP Right Cessation
1998
- 1998-03-10 GR GR980400481T patent/GR3026307T3/el unknown

Also Published As

Publication number	Publication date
EP0504335A1 (fr)	1992-09-23
CA2067233C (fr)	2001-04-10
JPH05502046A (ja)	1993-04-15
SE9002617D0 (sv)	1990-08-10
FI921582L (fi)	1992-04-09
AU8411891A (en)	1992-03-02
NO921407L (no)	1992-06-05
EP0504335B1 (fr)	1997-12-10
DE69128416T2 (de)	1998-07-09
HU9201211D0 (en)	1992-07-28
CA2067233A1 (fr)	1992-02-11
DK0504335T3 (da)	1998-08-24
IE912836A1 (en)	1992-02-12
ES2112862T3 (es)	1998-04-16
GR3026307T3 (en)	1998-06-30
FI921582A0 (fi)	1992-04-09
WO1992002555A1 (fr)	1992-02-20
NO921407D0 (no)	1992-04-09
AU632001B2 (en)	1992-12-10
HU219261B (en)	2001-03-28
DE69128416D1 (de)	1998-01-22
HUT61035A (en)	1992-11-30
ATE161018T1 (de)	1997-12-15
FI106264B (fi)	2000-12-29

Legal Events

Date	Code	Title	Description
2011-09-12	MK1K	Patent expired

Publication	Publication Date	Title
US5440014A (en)	1995-08-08	Fibronectin binding peptide
Ram et al.	2001	Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae
AU2011311321B2 (en)	2016-05-19	Clostridium difficile antigens
JP2809428B2 (ja)	1998-10-08	フィブロネクチン結合タンパク質
McGavin et al.	1991	Fibronectin binding determinants of the Staphylococcus aureus fibronectin receptor
NO300069B1 (no)	1997-04-01	Hybrid DNA-sekvens kodende for fibronektinbindende protein, vektorer og mikroorganismer inneholdende denne samt fremgangsmåte ved fremstilling derav
Donohue-Rolfe et al.	1991	Shiga toxin: purification, structure, and function
EP2844283B1 (fr)	2019-06-12	Antigènes de clostridium difficile
NO309095B1 (no)	2000-12-11	AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt fibronektinbindende peptid
JP2001503609A (ja)	2001-03-21	コアグラーゼ陰性ブドウ球菌に由来する、新規フィブリノーゲン結合たん白質
Shafer et al.	1993	Synthetic peptides of human lysosomal cathepsin G with potent antipseudomonal activity
US5789549A (en)	1998-08-04	Fibronectin binding protein
AU618803B2 (en)	1992-01-09	Pharmaceutical composition containing fibronectin binding protein
NO309865B1 (no)	2001-04-09	Subenhet-vaksine for Neisseria meningitidis-infeksjoner og tilsvarende rensede subenheter
US6030805A (en)	2000-02-29	Fibronectin binding protein as well as its preparation
JP2001238684A (ja)	2001-09-04	新規ｌｅｐ
AU692140B2 (en)	1998-06-04	Fibronectin binding protein as well as its preparation
AU4342499A (en)	2000-03-09	Streptokinase mutants
WO1994010330A9 (fr)	1994-06-23	Proteine de liaison de la fibronectine et sa preparation
KR20000068980A (ko)	2000-11-25	스트렙토코커스 유베리스 락토페린 결합 단백질
US20020081722A1 (en)	2002-06-27	Fibronectin binding protein as well as its preparation
IE83742B1 (en)		Fibronectin binding protein